Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial-Reference-Cited by-同舟云学术

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Published:2023-01 Issue:1 Volume:18 Page:93-105
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Zhou Caicun,Huang Dingzhi,Fan Yun,Yu Xinmin,Liu Yunpeng,Shu Yongqian,Ma Zhiyong,Wang Ziping,Cheng Ying,Wang Jie,Hu Sheng,Liu Zhihua,Poddubskaya Elena,Disel Umut,Akopov Andrey,Dvorkin Mikhail,Zheng Wenjuan,Ma Yiyuan,Wang Yan,Li Songzi,Yu Cunjing,Rivalland Gareth

Funder

BeiGene

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. SEER Cancer Statistics Review, 1975-2017;Howlader,2020

3. A banner year for immunotherapy and targeted therapy;Carlisle;Nat Rev Clin Oncol,2019

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

2. Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer;Discover Oncology;2024-08-31

3. Docetaxel‐Encapsulated Catalytic Pt/Au Nanotubes for Synergistic Chemo‐Photothermal Therapy of Triple‐Negative Breast Cancer;Advanced Healthcare Materials;2024-08-27

4. Living in LALA land? Forty years of attenuating Fc effector functions;Immunological Reviews;2024-08-19

5. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China;Frontiers in Public Health;2024-07-18